Identification of Microorganisms using Nucleic Acid Probes Reimbursement Policy
Customize your policy alerts
Sign up for Healthfirst Policy PO-RE-033v6 alerts
Get alerted when Policy PO-RE-033v6 changes without checking for updates manually.
Monitor payer policy activity
This reimbursement policy governs coverage of individual direct-probe, amplified-probe, and quantification nucleic acid tests used to identify microorganisms. Coverage is subject to the member's benefit coverage and code-specific criteria; simultaneous amplified-probe and quantification testing for the same organism in one encounter does not meet coverage criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.